p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy

Human Gene Therapy

Volumn 13, Issue 6, 2002, Pages 761-773

  Seki, Masafumi ^a   Iwakawa, Jun ^a   Cheng, Helen ^a   Cheng, Pi Wan ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM DERIVATIVE; CHOLESTEROL; DIMYRISTOYLOXYPROPYL 3 DIMETHYLHYDROXYETHYL AMMONIUM BROMIDE; PROTEIN P53; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUDE MOUSE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BETA-GALACTOSIDASE; CHOLESTEROL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IN SITU NICK-END LABELING; LIPIDS; LIPOSOMES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORIC MONOESTER HYDROLASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; QUATERNARY AMMONIUM COMPOUNDS; STAINING AND LABELING; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; MUS MUSCULUS;

EID: 0036210391     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402317322311     Document Type: Article

References (55)

1. Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli
2. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene
3. Gene therapy of prostate cancer p53, suicide genes, and other targets
4. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas
5. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
6. No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes
7. T-cell development in the absence of a thymus: The number, the phenotype, and the functional capacity of T lymphocytes in nude mice
8. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
9. Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin
10. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
11. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMCA/PTEN
12. Dissimilar anti-tumor reactions induced by tumor cells engineered with the interleukin-2 or interleukin-15 gene in nude mice
13. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement
14. The multiple roles of PTEN in tumor suppression
15. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer
16. Cancer statistics
17. A surprising function for the PTEN tumor suppressor
18. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes
19. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
20. An integrin-targeted non-viral vector for pulmonary gene therapy
21. Introduction of therapeutic cDNAs into the lungs of human and animals
22. Barriers to efficient airway epithelial gene transfer: Lessons from cystic fibrosis
23. Prostate carcinoma: Tissue culture cell lines
24. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
25. Novel therapies for advanced prostate cancer
26. Molecular and cellular biology of prostate cancer
27. TEP-1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor
28. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells
29. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
30. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphoinositol 3, 4, 5-triphosphate
31. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
32. tax of human T-lymphotropic virus type 1
33. P-TEN, the tumor suppressor from human chromosome 10q23, is a specificity phosphatase
34. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy
35. A note on qualifying follow-up in studies of failure time
36. Selective gene expression in hepatic tumor with trans-arterial delivery of DNA/liposome/transferrin complex
37. Elevated macrophage activity in nude mice
38. Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells
39. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation
40. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
41. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastasis
42. Oncogenes and tumor suppressor genes: Therapeutic implications
43. Identification of a candidate tumor suppressor gene, MMCA1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
44. Gene therapy for prostate cancer: Where are we now?
45. Antisense c-myc retroviral vector suppresses established human prostate cancer
46. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
47. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts
48. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
49. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
50. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro
51. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts
52. Genetic instability and p53 mutations in metastatic foci of mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine
53. Lectin enhancement of the lipofection efficiency in human lung carcinoma cells
54. Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells
55. Cellular immunity to viral antigens limits E1-deleted adenovirus for gene therapy